Homeopathy assuages side effects of Rx

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 5
Volume 18
Issue 5

Homeopathy can help cancer patients with skin irritation and mouth sores, according to a review involving 664 participants published in the Cochrane Database of Systematic Reviews (online issue 2, 2009).

Homeopathy can help cancer patients with skin irritation and mouth sores, according to a review involving 664 participants published in the Cochrane Database of Systematic Reviews (online issue 2, 2009).

Sosie Kassab, MD, director of the Royal London Homeopathic Hospital’s Complementary Cancer Service, and colleagues reviewed eight studies on homeopathic remedies.

In one study with 256 participants, researchers found skin irritation from radiotherapy was less in patients who used calendula ointment as opposed to the topical agent trolamine. In another study with 32 participants, the hemeopathic, Traumeel S, relieved mouth sores caused by chemotherapy better than placebo.

There is no convincing evidence to support the use of homeopathic medicines for adverse effects of cancer treatments other than skin irritation and mouth sores, Dr. Kassab said. “But very little research has been undertaken and more is required,” she said.

Most physicians are unaware that major, federally funded clinical trials on alternative medicine are currently underway (Arch Intern Med 169:670-679, 2009).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Related Content